TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| 2024 | 2023 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss available to common stockholders | $(30,045) | $(59,363) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 744 | 684 |
| Reduction in the carrying amount of right-of-use assets | 264 | 202 |
| Change in fair value of warrants and SEPA liability | 2,777 | 10,855 |
| Change in fair value of contingent earnout liabilities | (11,231) | (10,293) |
| Change in fair value of Initial OrbiMed Warrant and revenue base redemption liabilities | (670) | — |
| Non-cash interest expense | 604 | — |
| Loss on equity issuance | — | 5,874 |
| Extinguishment of tranche liability | — | (1,520) |
| Stock-based compensation expense | 5,441 | 1,402 |
| Allowance for credit losses | 187 | — |
| Loss on disposal of fixed assets | 23 | 44 |
| Amortization of debt issuance costs | 612 | — |
| Milestone payment to Dynavax | — | 1,000 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,719) | (1,979) |
| Inventory | (1,503) | (1,073) |
| Prepaid expenses | (1,708) | 1,032 |
| Deposits | 43 | — |
| Operating lease liabilities | (278) | (281) |
| Trade payables and accrued liabilities | (4,384) | 2,838 |
| Net cash used in operating activities | (40,843) | (50,578) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (345) | (588) |
| Milestone payment to Dynavax | — | (1,000) |
| Net cash used in investing activities | (345) | (1,588) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of preferred stock | — | 9,189 |
| Proceeds from the issuance of common stock | 15,537 | — |
| Proceeds from exercise of preferred stock warrants | — | 9,630 |
| Purchase of common stock warrants | — | (20) |
| Proceeds from Business Combination | — | 36,854 |
| Offering costs related to Business Combination | — | (1,116) |
| Debt issuance costs | (2,593) | — |
| Proceeds from the issuance of debt | 25,000 | — |
| Payments on finance lease liabilities | (84) | (87) |
| Proceeds from the exercise of stock options for common stock | 76 | 179 |
| Net cash provided by financing activities | 37,936 | 54,629 |
| (Decrease) increase in cash, cash equivalents and restricted cash | (3,252) | 2,463 |
| Cash, cash equivalents and restricted cash, beginning of period | 12,127 | 9,664 |
| Cash, cash equivalents and restricted cash, end of period | $8,875 | $12,127 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | 1,750 | 18 |
| Income taxes | 18 | 14 |
| Supplemental disclosure of noncash items: | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | 294 | — |
| Fixed asset purchases included in trade payables and accrued expenses | — | 19 |
|---|---|---|
| Prepaid warrant issuance costs | 1,700 | — |
| Fair value of initial warrants issued with OrbiMed debt | 362 | — |
| Fair value of revenue base redemption liability related to OrbiMed debt | 507 | — |
| Non-cash interest expense | 604 | — |
| Transfer of warrant liability to common stock upon exercise of warrant | 11,924 | — |
| Transfer of warrant liability to preferred stock upon exercise of warrants | — | 25,409 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.